Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Repare Therapeutics Inc. (RPTX : NSDQ)
 
 • Company Description   
Repare Therapeutics Inc. is an oncology company. It utilizes genome-wide, CRISPR-enabled SNIPRx(R) platform to discover and develop targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's product pipeline includes RP-3500, which is in clinical stage. Repare Therapeutics Inc. is based in St-Laurent, Canada.

Number of Employees: 152

 
 • Price / Volume Information   
Yesterday's Closing Price: $8.45 Daily Weekly Monthly
20 Day Moving Average: 205,874 shares
Shares Outstanding: 41.89 (millions)
Market Capitalization: $354.00 (millions)
Beta: 0.89
52 Week High: $35.75
52 Week Low: $8.07
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -28.09% -19.01%
12 Week -44.92% -39.45%
Year To Date -59.93% -50.35%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7210 Frederick-Banting Suite 100
-
St-Laurent,A8 H4S 2A1
CAN
ph: 857-412-7018
fax: -
investor@reparerx.com http://www.reparerx.com
 
 • General Corporate Information   
Officers
Lloyd M. Segal - President and Chief Executive Officer
Thomas Civik - Chairman
Steve Forte - Executive Vice President and Chief Financial Offic
Jerel Davis - Director
Todd Foley - Director

Peer Information
Repare Therapeutics Inc. (CORR.)
Repare Therapeutics Inc. (RSPI)
Repare Therapeutics Inc. (CGXP)
Repare Therapeutics Inc. (BGEN)
Repare Therapeutics Inc. (GTBP)
Repare Therapeutics Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 760273102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 41.89
Most Recent Split Date: (:1)
Beta: 0.89
Market Capitalization: $354.00 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.86 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.37
Price/Cash Flow: -
Price / Sales: 45.14
EPS Growth
vs. Year Ago Period: -43.10%
vs. Previous Quarter: -18.57%
Sales Growth
vs. Year Ago Period: 145.78%
vs. Previous Quarter: -94.07%
ROE
03/31/22 - -47.60
12/31/21 - -41.95
09/30/21 - -36.89
ROA
03/31/22 - -36.38
12/31/21 - -32.30
09/30/21 - -28.61
Current Ratio
03/31/22 - 9.37
12/31/21 - 10.02
09/30/21 - 11.98
Quick Ratio
03/31/22 - -
12/31/21 - 10.01
09/30/21 - 11.98
Operating Margin
03/31/22 - -1,533.38
12/31/21 - -1,406.68
09/30/21 - -10,941.61
Net Margin
03/31/22 - -1,533.38
12/31/21 - -1,406.68
09/30/21 - -10,941.61
Pre-Tax Margin
03/31/22 - -1,552.63
12/31/21 - -1,428.76
09/30/21 - -11,270.51
Book Value
03/31/22 - 6.17
12/31/21 - 6.91
09/30/21 - 5.88
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©